(HealthDay News) — A nomogram based on the inflammatory-nutritional score (INS) may help predict survival in patients with newly diagnosed multiple myeloma, according to a study published in the Journal of Inflammation Research.
Researchers conducted a retrospective analysis to assess the prognostic value of pretreatment inflammatory and nutritional parameters for predicting overall survival. The analysis included 442 patients with newly diagnosed multiple myeloma who were randomly divided into training and validation cohorts in a 8:2 ratio.
The INS was constructed with 6 inflammatory/nutritional variables, including the nutritional risk index, body mass index, neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio, platelet-lymphocyte ratio, and albumin-alkaline phosphatase ratio. The INS was merged with performance status, lactate dehydrogenase, age, and C-reactive protein to generate a nomogram for predictive optimization.
The nomogram had good predictive performance, with a C-index of 0.708 and 0.749 in the training and validation cohorts, respectively. Consistency between predicted and observed survival was demonstrated for both cohorts in calibration curves. The nomogram exhibited better performance than other staging systems for multiple myeloma in the time-dependent receiver operating characteristic curve analysis.
“The nomogram based on the INS exhibited good predictive accuracy and discriminative ability, suggesting that it can aid in predicting individual survival probability in patients with NDMM [newly diagnosed multiple myeloma],” the study authors wrote.